DOCSLIB.ORG

Phenergan® (Fen-Er-Gan) Promethazine Hydrochloride (PRO-Meth-Ar-Zine HIGH-Dro (H)-CLOR-Ride) Consumer Medicine Information (CMI)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phenergan® (Fen-Er-Gan) Promethazine Hydrochloride (PRO-Meth-Ar-Zine HIGH-Dro (H)-CLOR-Ride) Consumer Medicine Information (CMI) Phenergan® (fen-er-gan) Promethazine hydrochloride (PRO-meth-ar-zine HIGH-dro (h)-CLOR-ride) Consumer Medicine Information (CMI) What is in this leaflet Antihistamines help reduce allergic Do not take Phenergan if you are symptoms by preventing the effects also taking or have recently (within This leaflet answers some common of a substance called histamine. the last 14 days) taken monoamine questions about Phenergan. Histamine is produced by the body in oxidase inhibitors, a type of response to foreign substances that medicine used to treat depression. It does not contain all the available the body is allergic to. information. It does not take the Do not take Phenergan if you have place of talking to your pharmacist or Your pharmacist or doctor may have jaundice. doctor. recommended Phenergan for another Do not take this medicine if you reason. All medicines have risks and are receiving or have received high benefits. Your pharmacist or doctor Ask your pharmacist or doctor if doses of other CNS depressant has weighed the risks of you taking you have any questions about this medications (for example, drugs Phenergan against the benefits they medicine. that are used to treat anxiety and expect it will have for you. Phenergan must not be used in sleep disorders). If you have any concerns about children under 2 years of age, due Do not take this medicine if you taking this medicine, ask your to the potential for fatal have slowed breathing or heart pharmacist or doctor. respiratory depression. rate of any cause. Keep this leaflet with the medicine. This medicine may affect your Any person who is unconscious or ability to drive a car or operate in a coma must not be treated with You may need to read it again. machinery. Phenergan. Do not give Phenergan to newborn or premature babies. What Phenergan is Before you take it Do not use for children less than used for two years of age, due to the potential for fatal respiratory Phenergan is an antihistamine used to When you must not take it depression. treat a number of conditions: Do not take Phenergan if you have Do not take Phenergan if you are • allergies - allergic contact an allergy to: pregnant or plan to become dermatitis, hives, hayfever, bites • any medicine containing pregnant. and stings promethazine hydrochloride It may affect your developing baby if • respiratory symptoms due to • any of the ingredients listed at the you take it during pregnancy. Your allergies - runny nose end of this leaflet pharmacist or doctor will discuss the benefits and possible risks of taking • nausea and vomiting - motion Some of the symptoms of an allergic the medicine during pregnancy. sickness reaction may include: Do not take Phenergan if you are • assists in the management of the • shortness of breath breastfeeding or plan to symptoms of chicken pox and • wheezing or difficulty breathing breastfeed. measles by acting as a sedative • swelling of the face, lips, tongue It passes into the breast milk and • for short-term use in adults for or other parts of the body there is a possibility that the baby sedation on the advice of a may be affected. pharmacist or doctor - do not use • rash, itching or hives on the skin for more than 7-10 days PHENERGAN® 1 Do not take Phenergan after the Phenergan may delay the early They may differ from the expiry date (EXP) printed on the diagnosis of intestinal blockage information contained in this leaflet. pack. through preventing vomiting. Phenergan tablets are recommended If you take this medicine after the Phenergan may mask the warning for adults and children over 6 years expiry date has passed, it may not signs of ototoxicity e.g. salicylates of age. work as well. (damage to the inner ear) Phenergan elixir is recommended for Do not take Phenergan if the children 2-5 years of age. Taking other medicines packaging is torn or shows signs of Allergic Disorder tampering. Tell your pharmacist or doctor if Adults: One to three 25mg tablets as you are taking any other a single dose at night, or one to two Before you start to take it medicines, including any that you 10mg tablets, two to three times buy without a prescription from Tell your pharmacist or doctor if daily. you have allergies to: your pharmacy, supermarket or health food shop. Children 6-12 years: One to two • any other medicines 10mg tablets, or 10 to 25mL of the Some medicines and Phenergan may • any other substances, such as elixir as a single dose at night, or one interfere with each other. Phenergan foods, preservatives or dyes 10mg tablet, or 10mL of the elixir, may increase the sedative effect of two to three times daily. Tell your pharmacist or doctor if some drugs. These include: you have or have had any medical Children 2-5 years: 5-15mL of elixir • medicines used to treat conditions, especially the following: as a single dose at night, or 5mL of depression, especially elixir, two to three times daily. • kidney or liver disease monoamine oxidase inhibitors Sedation • epilepsy and tricyclic antidepressants For short term use in adults on the • cardiovascular disease • medicines used to help you sleep or relax (sedatives and advice of a pharmacist or doctor. • blood pressure problems hypnotics) Adults: One to three 25mg tablets as • bladder problems • anticholinergic agents such as a single dose at night. • breathing problems those used to treat Parkinson’s Travel Sickness disease. • glaucoma - an eye condition Adults: One 25mg tablet. • prostate problems • opioid analgesics, medicines Children 6-12 years: One 10mg used to treat pain • stomach ulcer or blockage tablet or 10mL of the elixir. • other antihistamines Tell your doctor if you plan to have Children 2-5 years: 5mL of elixir. • alcohol surgery. To be taken the night before travel Tell your pharmacist or doctor if These medicines may be affected by and repeated after 6 to 8 hours on the you take sedatives. Phenergan or may affect how well it following day if required. works. You may need different Tell your pharmacist or doctor if Nausea and Vomiting amounts of your medicines, or you you are pregnant or intend to may need to take different medicines. Adults: One 25mg tablet every 4 to 6 become pregnant. hours to a maximum daily dose of Your pharmacist and doctor will Phenergan is not recommended for four 25mg tablets. have more information on medicines use during pregnancy. If there is a to be careful with or avoid while Children 6-12 years: One 10mg need to consider Phenergan during taking this medicine. tablet or 10mL of the elixir, every 4 your pregnancy, your pharmacist or to 6 hours to a maximum daily dose doctor will discuss with you the of two 10mg tablets or 25mL of the benefits and risks of taking it. elixir. Do not take Phenergan if you are How to take it Children 2-5 years: 5mL of elixir breastfeeding or plan to every 4 to 6 hours to a maximum breastfeed. How much to take daily dose of 15mL. It passes into the breast milk and If you do not understand the Follow all directions given to you there is a possibility that the baby instructions on the carton or the by your pharmacist or doctor may be affected. label, ask your pharmacist or carefully. doctor for help. PHENERGAN® 2 Do not take more than the This may be harmful. should protect your skin from recommended dose. If you are not sure what to do, ask exposure to bright sunlight. Use this drug only as your pharmacist or doctor. Tell any other doctors, dentists, recommended. Do not exceed the If you have trouble remembering and pharmacists who are treating recommended dose. There have to take your medicine, ask your you that you are taking Phenergan. been case reports of promethazine pharmacist for some hints. If you are about to be started on abuse. any new medicine, tell your Use in the Elderly If you take too much pharmacist or doctor that you are If you are over 65 years of age, talk (overdose) taking Phenergan. to you pharmacist or doctor about Immediately telephone your doctor If you plan to have surgery that how much to take. or the Poisons Information Centre needs a general anaesthetic, tell Elderly patients are more likely to (in Australia, call 13 11 26; in New your doctor or dentist that you are have side effects from taking these Zealand, call 0800 764 766) for taking this medicine. medicines. advice or go to Accident and If you become pregnant while you Emergency at the nearest hospital, are taking this medicine, stop How to take it if you think that you or anyone else taking it and tell your doctor may have taken too much immediately. Tablets Phenergan. Talk to your pharmacist or doctor Swallow Phenergan tablets whole Do this even if there are no signs of if your symptoms do not improve. with a full glass of water. discomfort or poisoning. Your pharmacist or doctor will assess Elixir You may need urgent medical your condition and decide if you Measure out the amount of elixir to attention. should continue to take the medicine. be taken. If you take too much Phenergan, you may experience: Things you must not do How long to take it Adults Do not give Phenergan to anyone Phenergan should not usually be else, even if they have the same • drowsiness taken for more than 10 days in a condition as you. row. If your symptoms persist, see • convulsions and/or tremors Do not take Phenergan to treat any your pharmacist or doctor for • difficulty breathing other complaints unless your advice.
Load more

Recommended publications
  • Histamine and Antihistamines
    ACTA FACULTATIS MEDICAE NAISSENSIS UDC: 615.218 DOI: 10.1515/afmnai-2015-0001 Review article Histamine and Antihistamines Nikola Stojković1, Snežana Cekić2, Milica Ristov3, Marko Ristić1, Davor Đukić1, Maša Binić1, Dragan Virijević1 1University of Niš, Faculty of Medicine, PhD student, Serbia 2Institute of Physiology, University of Niš, Faculty of Medicine , Serbia 3Doctor of Medicine SUMMARY In recent years, there has been a steady increase in the prevalence of allergic diseases. Allergic immune response represents a complex network of cellular events involving numerous immune cells and mediators. It represents the interaction of innate and acquired immune response. The key role in the immune cascade is taken by histamine, a natural component of the body, which in the allergic inflammatory response is releasesd by the mast cells and basophils. The aim of this study was to highlight the role of histamine in allergic immunological events, their effect on Th1 and Th2 subpopulation of lymphocytes and the production of the corresponding cytokines, as well as the role of histamine blockers in the treatment of these conditions. Histamine achieves its effect by binding to the four types of its receptors, which are widely distributed in the body. Histamine blockers block a numerous effects of histamine by binding to these receptors. As a highly selective second-generation antihistamine, cetirizine not only achieves its effects by binding to H1 receptors, but also attenuates numerous events during the inflammatory process. Knowledge of the effects
    [Show full text]
  • Thioridazine Induces Apoptosis of Multidrug-Resistant Mouse Lymphoma Cells Transfected with the Human ABCB1 and Inhibits the Expression of P-Glycoprotein
    ANTICANCER RESEARCH 31: 4201-4206 (2011) Thioridazine Induces Apoptosis of Multidrug-resistant Mouse Lymphoma Cells Transfected with the Human ABCB1 and Inhibits the Expression of P-Glycoprotein GABRIELLA SPENGLER1,3, JOSEPH MOLNAR1, MIGUEL VIVEIROS2,4 and LEONARD AMARAL2,3,4 1Institute of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, Szeged, Hungary; 2Group of Mycobacteriology, Unit of Microbiology and 3Unit of Parasitology and Medical Microbiology (UPMM), Institute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, Lisboa, Portugal; 4Cost Action BM0701 (ATENS) of the European Commission, Brussels, Belgium Abstract. Aim: Chlorpromazine has activity against a large therapeutic aspects, and low availability of effective but also variety of cancer types. However, this phenothiazine produces costly forms of therapy (chemotherapy, radiotherapy). a plethora of serious side-effects. We have studied thioridazine Regardless of economic support, chemotherapy of cancer is (TZ), a phenothiazine neuroleptic that is much milder, for highly problematic, especially when therapy promotes the activity against multidrug-resistant (MDR) cancer cells, as development of multidrug resistance (MDR), hence cancer well as against the overexpressed ABCB1 transporter (P- becomes refractory not only to the initial chemotherapeutic glycoprotein) that is the cause for the MDR phenotype of these agent, but to many other anticancer drugs as well (1, 2). The cancer cells. Materials and Methods: MDR mouse T- development of an MDR phenotype of cancer cell has been lymphoma cells, transfected with the human gene ABCB1 that known for many decades to be due to the overexpression of codes for the transporter ABCB1, were incubated with TZ for transporters that extrude the anticancer agent before it various periods of time and examined for evidence of reaches its intended target (3).
    [Show full text]
  • FDA Approved Drugs with Broad Anti-Coronaviral Activity Inhibit SARS-Cov-2 in Vitro
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.25.008482; this version posted March 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro Stuart Weston1, Rob Haupt1, James Logue1, Krystal Matthews1 and Matthew B. Frieman*1 1 - Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 W. Baltimore St., Room 380, Baltimore, MD, 21201, USA *Corresponding author. Email: [email protected] Key words: SARS-CoV-2, nCoV-2019, COVID-19, drug repurposing, FDA approved drugs, antiviral therapeutics, pandemic, chloroquine, hydroxychloroquine AbstraCt SARS-CoV-2 emerged in China at the end of 2019 and has rapidly become a pandemic with over 400,000 recorded COVID-19 cases and greater than 19,000 recorded deaths by March 24th, 2020 (www.WHO.org) (1). There are no FDA approved antivirals or vaccines for any coronavirus, including SARS-CoV-2 (2). Current treatments for COVID-19 are limited to supportive therapies and off-label use of FDA approved drugs (3). Rapid development and human testing of potential antivirals is greatly needed. A potentially quicker way to test compounds with antiviral activity is through drug re-purposing (2, 4). Numerous drugs are already approved for use in humans and subsequently there is a good understanding of their safety profiles and potential side effects, making them easier to test in COVID-19 patients.
    [Show full text]
  • Download Large Text CMI (PDF)
    Children's Paedamin Antihistamine Oral Liquid Decongestant and Antihistamine Children 6-12 years Consumer Medicine Information What is in this leaflet? • Itchy, watery eyes Before you give • Nasal congestion Children's Paedamin This leaflet answers some common Children's Paedamin Decongestant Decongestant and questions about Children's and Antihistamine contains Antihistamine Paedamin® Decongestant and Diphenhydramine Hydrochloride Antihistamine. and Phenylephrine Hydrochloride. When you must not give it It does not contain all the available Diphenhydramine Hydrochloride Do not use Children's Paedamin information. It does not take the belongs to a group of medicines Decongestant and Antihistamine if place of talking to your doctor or called 'antihistamines'. you/ your child have an allergy to: pharmacist. Antihistamines help reduce allergic All medicines have risks and symptoms, such as sneezing, runny • any medicine containing benefits. Your doctor or pharmacist nose or itchy, watery eyes, by Diphenhydramine has weighed the risks of you/your preventing the effects of a substance Hydrochloride or other child taking Children's Paedamin called histamine. Histamine is antihistamines Decongestant and Antihistamine produced by the body in response to • any medicine containing against the benefits they expect it foreign substances that the body is Phenylephrine Hydrochloride will have for you. allergic to. • any of the ingredients listed at If you have any concerns about Phenylephrine Hydrochloride the end of this leaflet taking this medicine, ask your belongs to a group of medicines Some of the symptoms of an doctor or pharmacist. called decongestants. allergic reaction may include: Keep this leaflet with the It works by reducing congestion in • shortness of breath medicine.
    [Show full text]
  • A Drug Repositioning Approach Identifies Tricyclic Antidepressants As Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors
    Published OnlineFirst September 26, 2013; DOI: 10.1158/2159-8290.CD-13-0183 RESEARCH ARTICLE A Drug Repositioning Approach Identifi es Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors Nadine S. Jahchan 1 , 2 , Joel T. Dudley 1 , Pawel K. Mazur 1 , 2 , Natasha Flores 1 , 2 , Dian Yang 1 , 2 , Alec Palmerton 1 , 2 , Anne-Flore Zmoos 1 , 2 , Dedeepya Vaka 1 , 2 , Kim Q.T. Tran 1 , 2 , Margaret Zhou 1 , 2 , Karolina Krasinska 3 , Jonathan W. Riess 4 , Joel W. Neal 5 , Purvesh Khatri 1 , 2 , Kwon S. Park 1 , 2 , Atul J. Butte 1 , 2 , and Julien Sage 1 , 2 Downloaded from cancerdiscovery.aacrjournals.org on September 29, 2021. © 2013 American Association for Cancer Research. Published OnlineFirst September 26, 2013; DOI: 10.1158/2159-8290.CD-13-0183 ABSTRACT Small cell lung cancer (SCLC) is an aggressive neuroendocrine subtype of lung cancer with high mortality. We used a systematic drug repositioning bioinformat- ics approach querying a large compendium of gene expression profi les to identify candidate U.S. Food and Drug Administration (FDA)–approved drugs to treat SCLC. We found that tricyclic antidepressants and related molecules potently induce apoptosis in both chemonaïve and chemoresistant SCLC cells in culture, in mouse and human SCLC tumors transplanted into immunocompromised mice, and in endog- enous tumors from a mouse model for human SCLC. The candidate drugs activate stress pathways and induce cell death in SCLC cells, at least in part by disrupting autocrine survival signals involving neurotransmitters and their G protein–coupled receptors. The candidate drugs inhibit the growth of other neuroendocrine tumors, including pancreatic neuroendocrine tumors and Merkel cell carcinoma.
    [Show full text]
  • OTC DOSING GUIDE Benadryl
    OTC DOSING GUIDE Benadryl Our Dosing Guide gives dosages for common over-the-counter medications used in children. These medications are dosed according to weight. To calculate your child’s dose, look up his or her weight in the Dosing Guide and read across to the proper dose for each medicine listed. If you do not know your child’s weight and if your child is too young to stand on bathroom scales, a simple way to determine his or her weight is to first weigh both you and your child as you hold him. Then weigh yourself alone. Subtracting these two numbers will give you a fairly accurate weight for your child. The doses listed in the Dosing Chart are standard doses which are safe for your child. In some situations we recommend doses of these medications which may be slightly higher or lower than the doses recommended on the packaging of the medication. This should not concern you. If our advice calls for doses which are dramatically different, please ask us the reason for this. Abbreviations: mg=milligram tsp=teaspoon ml=milliliter cc=cubic centimeter dppr=dropperful 1 cc=1 ml 1 tsp=5 cc If your child takes an overdose of any medication, call Poison Control right away. The phone number is 1-800-376-4766 or 686-6161. CHILDREN’S BENADRYL ALLERGY LIQUID (Generic Name: Diphenhydramine) (Antihistamine) NEVER GIVE TO INFANTS LESS THAN 6 MONTHS OLD. DO NOT GIVE TO CHILDREN LESS THAN 2 YEARS OLD UNLESS ADVISED BY A PHYSICIAN. Dosage: Every 4 -6 hours.
    [Show full text]
  • Doxylamine Succinate-Pyridoxine Hydrochloride
    Doxylamine succinate-pyridoxine hydrochloride This sheet is about exposure to doxylamine succinate-pyridoxine hydrochloride in pregnancy and while breastfeeding. This information should not take the place of medical care and advice from your healthcare providers. What is doxylamine succinate-pyridoxine hydrochloride? The combination of 10mg of doxylamine succinate and 10mg of pyridoxine hydrochloride is a medication used to treat nausea and vomiting of pregnancy (NVP), also called “morning sickness.” For more information on NVP, please see the MotherToBaby fact sheet Nausea and Vomiting of Pregnancy (https://mothertobaby.org/fact-sheets/nausea-vomiting-pregnancy-nvp/pdf/). Doxylamine succinate is an antihistamine. Antihistamines lessen the symptoms of allergic reactions and colds and help to treat insomnia (hard time sleeping). Pyridoxine hydrochloride is a form of vitamin B6. In the United States, the combination of doxylamine and pyridoxine has been sold under the name Diclegis® since 2013. In Canada, it has been sold under the brand name Diclectin®. Diclegis® and Diclectin® are delayed-release tablets available by prescription. Delayed-release means that the tablet coating prevents the ingredients from being absorbed too quickly by the body. Doxylamine succinate and/or pyridoxine hydrochloride may also be available as over-the- counter medicines. I take doxylamine succinate-pyridoxine hydrochloride. Can it make it harder for me to get pregnant? Based on the data available, it is not known if doxylamine succinate-pyridoxine hydrochloride can make it harder to become pregnant. I just found out I am pregnant. Should I stop taking doxylamine succinate-pyridoxine hydrochloride? Talk with your healthcare providers before making any changes to how you take your medication(s).
    [Show full text]
  • Light Scattering Studies of Amphiphilic Drugs Promethazine Hydrochloride and Imipramine Hydrochloride in Aqueous Electrolyte Solutions
    12962 J. Phys. Chem. B 2008, 112, 12962–12967 Light Scattering Studies of Amphiphilic Drugs Promethazine Hydrochloride and Imipramine Hydrochloride in Aqueous Electrolyte Solutions Md. Sayem Alam,† Goutam Ghosh,‡ and Kabir-ud-Din*,† Department of Chemistry, Aligarh Muslim UniVersity, Aligarh-202 002, India, and UGC-DAE Consortium for Scientific Research, Trombay, Mumbai- 400 085, India ReceiVed: May 13, 2008; ReVised Manuscript ReceiVed: August 1, 2008 Two amphiphilic drugs, promethazine hydrochloride (PMT) and imipramine hydrochloride (IMP), have been studied using both static and dynamic light scattering techniques. Due to having rigid tricyclic hydrophobic moieties in their molecules, these drugs show interesting association behavior. The static light scattering (SLS) measurements show that the self-association commenced above a well-defined critical micellar concentration (cmc), which decreases with increasing NaBr concentration. The Gibbs energy of micellization, 0 ∆GM, in all cases, is negative. The colloidal stability of the system in terms of the interparticle interaction at different NaBr concentrations was studied using the dynamic light scattering (DLS) technique. The experimentally evaluated interparticle interaction parameter (kD) was compared with the Derjaguin-Landau- Verwey-Overbeek (DLVO) model. Interestingly, these two drugs with similar molecular structure show difference in their interparticle interactions, e.g., PMT showed complete agreement with the DLVO model whereas IMP showed clear deviation from this model at lower concentrations and agreement at higher concentrations of NaBr. 1. Introduction SCHEME 1: Molecular Structure of Promethazine Hydrochloride, PMT (a), and Imipramine Hydrochloride, Many drug molecules are amphiphilic and self-associate in IMP (b) a surfactant-like manner in aqueous environment to form small aggregates.
    [Show full text]
  • Doxylamine/Pyridoxine
    BonjestaTM (doxylamine/pyridoxine) – New Drug Approval • On November 7, 2016, the FDA approved Duchesnay’s Bonjesta (doxylamine/pyridoxine) for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. — Bonjesta has not been studied in women with hyperemesis gravidarum. • Bonjesta is a fixed dose combination product containing an antihistamine (doxylamine) and a vitamin B6 analog (pyridoxine). The exact mechanism of Bonjesta is not known. — Doxylamine/pyridoxine is also available as Diclegis®, which contains 10 mg of doxylamine and 10 mg of pyridoxine as delayed-release tablets for the same indication. • There have been no efficacy and safety trials for Bonjesta. However, a placebo-controlled study was conducted to support the safety and efficacy of 10 mg doxylamine succinate and 10 mg pyridoxine hydrochloride tablets (a different formulation and dosage strength than Bonjesta) in the treatment of nausea and vomiting of pregnancy. • Bonjesta is contraindicated in women with known hypersensitivity to doxylamine, other ethanolamine derivative antihistamines, or pyridoxine or any inactive ingredient in the formulation; monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of Bonjesta. • Warnings and precautions of Bonjesta include somnolence and concomitant medical conditions. • The most common adverse event (≥ 5% and exceeding placebo) with combination 10 mg doxylamine and 10 mg pyridoxine tablets was somnolence. • The recommended dose of Bonjesta is one tablet orally at bedtime on day 1. If the dose adequately controls symptoms the next day, the patient may continue taking one tablet daily at bedtime only. However, if symptoms persist on day 2, the dose may be increased to one tablet in the morning and one tablet at bedtime.
    [Show full text]
  • Doxepin (Dox-E-Pin) Description: Tricyclic Antidepressant; Antihistamine Other Names for This Medication: Sinequan®, Silenor® Common Dosage Forms: Veterinary: None
    Prescription Label Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long): Prescribing Veterinarian's Name & Contact Information: Refills: [Content to be provided by prescribing veterinarian] Doxepin (dox-e-pin) Description: Tricyclic Antidepressant; Antihistamine Other Names for this Medication: Sinequan®, Silenor® Common Dosage Forms: Veterinary: None. Human: 3 mg, 6 mg, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, & 150 mg capsules; 10 mg/mL oral liquid concentrates. This information sheet does not contain all available information for this medication. It is to help answer commonly asked questions and help you give the medication safely and effectively to your animal. If you have other questions or need more information about this medication, contact your veterinarian or pharmacist. Key Information When used as an antihistamine, doxepin should be used on a regular, ongoing basis in animals that respond to it. This drug works better if used before exposure to an allergen (eg, pollens). When used for behavior modification, it may take several days to weeks to determine if doxepin is effective. May be given with or without food. If your animal vomits or acts sick after receiving the drug on an empty stomach, try giving the next dose with food or a small treat. If vomiting continues, contact your veterinarian. Most common side effects are sleepiness, dry mouth, and constipation. Be sure your animal always has access to plenty of fresh, clean water. Rare side effects that can be serious (contact veterinarian immediately) include abnormal bleeding, lack of an appetite, seizures, collapse, or profound sleepiness.
    [Show full text]
  • HALDOL Decanoate 50 (Haloperidol)
    HALDOL® Decanoate 50 (haloperidol) HALDOL® Decanoate 100 (haloperidol) For IM Injection Only WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. HALDOL Decanoate is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS). DESCRIPTION Haloperidol decanoate is the decanoate ester of the butyrophenone, HALDOL (haloperidol). It has a markedly extended duration of effect. It is available in sesame oil in sterile form for intramuscular (IM) injection. The structural formula of haloperidol decanoate, 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-4 piperidinyl decanoate, is: Haloperidol decanoate is almost insoluble in water (0.01 mg/mL), but is soluble in most organic solvents.
    [Show full text]
  • Histamine and Antihistamines Sites of Action Conditions Which Cause Release Aron H
    Learning Objectives I Histamine Pharmacological effects Histamine and Antihistamines Sites of action Conditions which cause release Aron H. Lichtman, Ph.D. Diagnostic uses Associate Professor II Antihistamines acting at the H1 and H2 receptor Pharmacology and Toxicology Pharmacological effects Mechanisms of action Therapeutic uses Side effects and drug interactions Be familiar with the existence of the H3 receptor III Be able to describe the main mechanism of action of cromolyn sodium and its clinical uses Histamine Pharmacology First autacoid to be discovered. (Greek: autos=self; Histamine Formation akos=cure) Synthesized in 1907 Synthesized in mammalian tissues by Demonstrated to be a natural constituent of decarboxylation of the amino acid l-histidine mammalian tissues (1927) Involved in inflammatory and anaphylactic reactions. Local application causes swelling redness, and edema, mimicking a mild inflammatory reaction. Large systemic doses leads to profound vascular changes similar to those seen after shock or anaphylactic origin Histamine Stored in complex with: Heparin Chondroitin Sulfate Eosinophilic Chemotactic Factor Neutrophilic Chemotactic Factor Proteases 1 Conditions That Release Histamine 1. Tissue injury: Any physical or chemical agent that injures tissue, skin or mucosa are particularly sensitive to injury and will cause the immediate release of histamine from mast cells. 2. Allergic reactions: exposure of an antigen to a previously sensitized (exposed) subject can immediately trigger allergic reactions. If sensitized by IgE antibodies attached to their surface membranes will degranulate when exposed to the appropriate antigen and release histamine, ATP and other mediators. 3. Drugs and other foreign compounds: morphine, dextran, antimalarial drugs, dyes, antibiotic bases, alkaloids, amides, quaternary ammonium compounds, enzymes (phospholipase C).
    [Show full text]